Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

CUG-binding protein 1 (CUGBP1) expression and prognosis of non-small cell lung cancer.

Jiao W, Zhao J, Wang M, Wang Y, Luo Y, Zhao Y, Tang D, Shen Y.

Clin Transl Oncol. 2013 Oct;15(10):789-95. doi: 10.1007/s12094-013-1005-5. Epub 2013 Jan 29.

PMID:
23359188
2.

Prognostic impact of CUG-binding protein 1 expression and vascular invasion after radical surgery for stage IB nonsmall cell lung cancer.

Zhao J, Zhao Y, Xuan Y, Jiao W, Qiu T, Wang Z, Luo Y.

Indian J Cancer. 2015 Dec;52 Suppl 2:e125-9. doi: 10.4103/0019-509X.172509.

3.

Insulin-like growth factor receptor 1 mRNA expression as a prognostic marker in advanced non-small cell lung cancer.

Vilmar A, Santoni-Rugiu E, Cillas JG, Huarriz M, Sørensen JB.

Anticancer Res. 2014 Jun;34(6):2991-6.

PMID:
24922664
4.

Analysis of MAT3 gene expression in NSCLC.

Zheng S, Du Y, Chu H, Chen X, Li P, Wang Y, Ma Y, Wang H, Zang W, Zhang G, Zhao G.

Diagn Pathol. 2013 Oct 9;8:166. doi: 10.1186/1746-1596-8-166.

5.

Gene diagnosis of micrometastases in regional lymph nodes of patients with stage I non-small cell lung cancer: impact on staging and prognosis.

Li J, Li ZN, Yu LC, Shi SB, Ge LP, Wu JR, Hu YM.

Clin Transl Oncol. 2013 Nov;15(11):882-8. doi: 10.1007/s12094-013-1017-1. Epub 2013 Feb 12.

PMID:
23404657
6.
7.

High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer.

Liu XG, Zhu WY, Huang YY, Ma LN, Zhou SQ, Wang YK, Zeng F, Zhou JH, Zhang YK.

Med Oncol. 2012 Jun;29(2):618-26. doi: 10.1007/s12032-011-9923-y. Epub 2011 Apr 24.

PMID:
21516486
8.
9.

Increased human telomerase reverse transcriptase (hTERT) mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer.

Metzger R, Vallbohmer D, Müller-Tidow C, Higashi H, Bollschweiler E, Warnecke-Eberz U, Brabender J, Baldus SE, Xi H, Berdel WE, Serve H, Hoelscher AH, Schneider PM.

Anticancer Res. 2009 Apr;29(4):1157-62.

10.

Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer.

Miura N, Nakamura H, Sato R, Tsukamoto T, Harada T, Takahashi S, Adachi Y, Shomori K, Sano A, Kishimoto Y, Ito H, Hasegawa J, Shiota G.

Cancer Sci. 2006 Dec;97(12):1366-73.

11.

Down-regulation of lysyl oxidase-like 2 (LOXL2) is associated with disease progression in lung adenocarcinomas.

Zhan P, Shen XK, Qian Q, Zhu JP, Zhang Y, Xie HY, Xu CH, Hao KK, Hu W, Xia N, Lu GJ, Yu LK.

Med Oncol. 2012 Jun;29(2):648-55. doi: 10.1007/s12032-011-9959-z. Epub 2011 Apr 26.

PMID:
21519871
12.

Ornithine decarboxylase mRNA expression in curatively resected non-small-cell lung cancer.

Grimminger PP, Schneider PM, Metzger R, Vallböhmer D, Danenberg KD, Danenberg PV, Hölscher AH, Brabender J.

Clin Lung Cancer. 2010 Mar 1;11(2):114-9. doi: 10.3816/CLC.2010.n.015.

PMID:
20199977
13.

A gene signature combining the tissue expression of three angiogenic factors is a prognostic marker in early-stage non-small cell lung cancer.

Sanmartín E, Sirera R, Usó M, Blasco A, Gallach S, Figueroa S, Martínez N, Hernando C, Honguero A, Martorell M, Guijarro R, Rosell R, Jantus-Lewintre E, Camps C.

Ann Surg Oncol. 2014 Feb;21(2):612-20. doi: 10.1245/s10434-013-3330-x. Epub 2013 Oct 22.

PMID:
24145997
14.

Prognostic significance of TIMP-1 in non-small cell lung cancer.

Pesta M, Kulda V, Kucera R, Pesek M, Vrzalova J, Liska V, Pecen L, Treska V, Safranek J, Prazakova M, Vycital O, Bruha J, Holubec L, Topolcan O.

Anticancer Res. 2011 Nov;31(11):4031-8.

PMID:
22110238
15.

Cytoplasmic Ape1 expression elevated by p53 aberration may predict survival and relapse in resected non-small cell lung cancer.

Wu HH, Chu YC, Wang L, Tsai LH, Lee MC, Chen CY, Shieh SH, Cheng YW, Lee H.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S336-47. doi: 10.1245/s10434-012-2431-2. Epub 2012 Jun 12.

PMID:
22688662
16.

Expression of caveolin-1 is correlated with disease stage and survival in lung adenocarcinomas.

Zhan P, Shen XK, Qian Q, Wang Q, Zhu JP, Zhang Y, Xie HY, Xu CH, Hao KK, Hu W, Xia N, Lu GJ, Yu LK.

Oncol Rep. 2012 Apr;27(4):1072-8. doi: 10.3892/or.2011.1605. Epub 2011 Dec 21.

17.

Vascular endothelial growth factor receptor 2 gene polymorphisms as predictors for tumor recurrence and overall survival in non-small-cell lung cancer.

Uzunoglu FG, Kaufmann C, Wikman H, Güngör C, Bohn BA, Nentwich MF, Reeh M, Pantel K, Bockhorn M, Kutup A, Mann O, Izbicki JR, Vashist YK.

Ann Surg Oncol. 2012 Jul;19(7):2159-68. doi: 10.1245/s10434-012-2227-4. Epub 2012 Mar 7.

PMID:
22395975
18.

Decreased expression of ING2 gene and its clinicopathological significance in Chinese NSCLC patients.

Pan YQ, Zhang X, Xu DP, Bao WG, Lin AF, Xu HH, Yan WH.

Neoplasma. 2014;61(4):468-75. doi: 10.4149/neo_2014_058.

PMID:
24712846
19.

Clinical significance of expression of cancer/testis antigen and down-regulation of HLA class-I in patients with stage I non-small cell lung cancer.

Hanagiri T, Shigematsu Y, Shinohara S, Takenaka M, Oka S, Chikaishi Y, Nagata Y, Baba T, Uramoto H, So T, Yamada S.

Anticancer Res. 2013 May;33(5):2123-8.

PMID:
23645764
20.

High Sam68 expression predicts poor prognosis in non-small cell lung cancer.

Zhang Z, Xu Y, Sun N, Zhang M, Xie J, Jiang Z.

Clin Transl Oncol. 2014 Oct;16(10):886-91. doi: 10.1007/s12094-014-1160-3. Epub 2014 Feb 13.

PMID:
24522888

Supplemental Content

Support Center